Back to everyone

Chris Ashton

Advisor, Life Sciences

Chris Ashton

Chris joined Oxford Science Enterprises in December 2019 and advises the Life Sciences team.

He is a seasoned biotech entrepreneur with over 35 years’ experience in the biotechnology industry.

Chris has considerable experience of leading and growing early-stage companies and the transition to mid-stage clinical development organisations. He also has extensive international transactional experience across both listed and private companies including fundraising, licensing and M&A activities.

Chris was formerly a Partner at Syncona, a FTSE250 company, where he was also founding CEO of Achilles Therapeutics (NASDAQ: ACHL). Prior to this he was CEO of Argenta Discovery, which was sold to Galapagos NV (Euronext and NASDAQ: GLPG), and Pulmagen Therapeutics.

Chris holds a PhD from the University of Manchester and carried out post-doctoral research at the Massachusetts Institute of Technology.

Chris sits on the board of

  • OMass Therapeutics
  • PepGen

Meet everyone in the

Life Sciences Team

Claire Brown
Claire BrownPartner, Life Sciences
Craig Fox
Craig FoxOperating Partner, Life Sciences
Jon Hepple
Jon HeppleAdvisor, Life Sciences
Katharina Ramshorn
Katharina RamshornAnalyst
Katya Smirnyagina
Katya SmirnyaginaSenior Partner, Life Sciences
Sally Dewhurst
Sally DewhurstPrincipal, Life Sciences
Sanne de Jongh
Sanne de JonghPartner, Life Sciences
Selina Greuel
Selina GreuelAssociate